ArQule, Inc. (ARQL) Upgraded at ValuEngine
ValuEngine upgraded shares of ArQule, Inc. (NASDAQ:ARQL) from a strong sell rating to a sell rating in a research note issued to investors on Friday.
Separately, Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $1.25 target price on the stock in a report on Thursday, September 28th.
Shares of ArQule (NASDAQ:ARQL) opened at $1.40 on Friday. ArQule has a fifty-two week low of $0.92 and a fifty-two week high of $1.68. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.45 and a quick ratio of 3.45.
ArQule (NASDAQ:ARQL) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.02. During the same quarter last year, the business earned ($0.08) EPS. equities research analysts expect that ArQule will post -0.39 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “ArQule, Inc. (ARQL) Upgraded at ValuEngine” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/21/arqule-inc-arql-upgraded-at-valuengine.html.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new stake in shares of ArQule in the 3rd quarter valued at $2,220,000. First Eagle Investment Management LLC raised its holdings in shares of ArQule by 5.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock valued at $13,807,000 after purchasing an additional 591,421 shares in the last quarter. Curbstone Financial Management Corp raised its holdings in shares of ArQule by 100.0% in the 3rd quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 52,286 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of ArQule by 0.9% in the 2nd quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 1,385 shares in the last quarter. Institutional investors and hedge funds own 50.49% of the company’s stock.
ArQule Company Profile
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.